Key clinical point: Radiation could be safe as bridging therapy to axicabtagene ciloleucel chimeric antigen receptor T-cell therapy in patients with advanced diffuse large B-cell lymphoma.
Major finding: At final follow-up, the best objective response rate was 81.8%, with complete response achieved in 45% of patients.
Study details: A case series of 12 patients with relapsed/refractory diffuse large B-cell lymphoma.
Disclosures: No funding sources were reported. The authors reported financial affiliations with Atara Biotherapeutics, AstraZeneca, Celgene, GlaxoSmithKline, Novartis, Precision Biosciences, and several others.
Sim AJ et al. Int J Radiat Oncol Biol Phys. 2019 Jun 5. doi: 10.1016/j.ijrobp.2019.05.065.